Fas-associated death domain protein and adenosine partnership: Fad in RA

Rheumatology (United Kingdom)

Volumn 51, Issue 6, 2012, Pages 964-975

  Vilmont, Vaérie ^a,b,c   Tourneur, Léa ^a,b,c   Chiocchia, Gilles ^a,b,c,d  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c Sorbonne Paris Cité ^*  (France)

^d HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Adenosine receptors; FADD; Inflammation; Rheumatoid arthritis; Secretion

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE; ADENOSINE RECEPTOR; DEATH RECEPTOR; DEATH RECEPTOR 3; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FAS ASSOCIATED DEATH DOMAIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; METHOTREXATE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG TARGETING; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; NONHUMAN; OSTEOARTHRITIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

ADENOSINE; ARTHRITIS, RHEUMATOID; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HUMANS; SIGNAL TRANSDUCTION;

EID: 84861469413     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker402     Document Type: Review

References (82)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903-11.
2. Ma Y, Liu H, Tu-Rapp H et al. Fas ligation on macrophages enhances IL-1R1-Toll-like receptor signaling and promotes chronic inflammation. Nat Immunol 2004;5:380-7.
3. Ottonello L, Cutolo M, Frumento G et al. Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. Rheumatology 2002;41:1249-60.
4. Sottofattori E, Anzaldi M, Ottonello L. HPLC determination of adenosine in human synovial fluid. J Pharm Biomed Anal 2001;24:1143-6.
5. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5: 247-64.
6. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006;65:845-51.
7. Kastbom A, Strandberg G, Lindroos A et al. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085-9.
8. Laurent L, Clavel C, Lemaire O et al. Fcg receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins. Ann Rheum Dis 2011;70:1052-9.
9. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 7:391-8.
10. Shu HB, Hu WH, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 1999;65:680-3.
11. Wu Y, Bressette D, Carrell JA et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 2000;275:35478-85.
12. Xia XZ, Treanor J, Senaldi G et al. TACI is a TRAFinteracting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med 2000;192:137-43.
13. Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003;5(Suppl. 4):S1-6.
14. Woo YJ, Yoon BY, Jhun JY et al. Regulation of B cell activating factor (BAFF) receptor expression by NF-κB signaling in rheumatoid arthritis B cells. Exp Mol Med 43: 350-7.
15. Hayashida K, Shimaoka Y, Ochi T et al. Rheumatoid arthritis synovial stromal cells inhibit apoptosis and up-regulate Bcl-xL expression by B cells in a CD49/CD29-CD106-dependent mechanism. J Immunol 2000;164:1110-6.
16. Perlman H, Georganas C, Pagliari LJ et al. Bcl-2 expression in synovial fibroblasts is essential for maintaining mitochondrial homeostasis and cell viability. J Immunol 2000;164:5227-35.
17. Salmon M, Scheel-Toellner D, Huissoon AP et al. Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 1997;99:439-46.
18. Smolewska E, Stanczyk J, Robak T et al. Inhibited apoptosis of synovial fluid lymphocytes in children with juvenile idiopathic arthritis is associated with increased expression of myeloid cell leukemia 1 and XIAP proteins. J Rheumatol 2006;33:1684-90.
19. Zhang Q, Badell IR, Schwarz EM et al. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. Arthritis Rheum 2005;52:2708-18.
20. Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev 1999;13:239-52.
21. Gagarina V, Carlberg AL, Pereira-Mouries L et al. Cartilage oligomeric matrix protein protects cells against death by elevating members of the IAP family of survival proteins. J Biol Chem 2008;283:648-59.
22. Mayer BA, Rehberg M, Erhardt A et al. Inhibitor of apoptosis proteins as novel targets in inflammatory processes. Arterioscler Thromb Vasc Biol 2011;31: 2240-50.
23. Grassi F, Piacentini A, Cristino S et al. Inhibition of CD95 apoptotic signaling by interferon-gamma in human osteoarthritic chondrocytes is associated with increased expression of FLICE inhibitory protein. Arthritis Rheum 2004;50:498-506.
24. Catrina AI, Ulfgren AK, Lindblad S et al. Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann Rheum Dis 2002;61:934-6.
25. Ha JE, Choi YE, Jang J et al. FLIP and MAPK play crucial roles in the MLN51-mediated hyperproliferation of fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis. Febs J 2008;275:3546-55.
26. Smith MD, Weedon H, Papangelis V et al. Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Rheumatology 49:862-75.
27. Chinnaiyan AM, O'Rourke K, Tewari M et al. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81: 505-12.
28. Chaudhary PM, Eby M, Jasmin A et al. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kB pathway. Immunity 1997;7:821-30.
29. Schneider P, Thome M, Burns K et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 1997;7:831-6.
30. Schneider-Brachert W, Tchikov V, Neumeyer J et al. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 2004;21:415-28.
31. Chinnaiyan AM, O'Rourke K, Yu GL et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996;274:990-2.
32. Nagata S. Apoptosis by death factor. Cell 1997;88: 355-65.
33. Tourneur L, Chiocchia G. FADD: a regulator of life and death. Trends Immunol 31:260-9.
34. Yeh WC, Pompa JL, McCurrach ME et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 1998;279:1954-8.
35. Zhang J, Cado D, Chen A et al. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 1998;392:296-300.
36. Zhang J, Kabra NH, Cado D et al. FADD-deficient T cells exhibit a disaccord in regulation of the cell cycle machinery. J Biol Chem 2001;276:29815-8.
37. Newton K, Harris AW, Strasser A. FADD/MORT1 regulates the pre-TCR checkpoint and can function as a tumour suppressor. Embo J 2000;19:931-41.
38. Imtiyaz HZ, Rosenberg S, Zhang Y et al. The Fas-associated death domain protein is required in apoptosis and TLR-induced proliferative responses in B cells. J Immunol 2006;176:6852-61.
39. Balachandran S, Thomas E, Barber GN. A FADDdependent innate immune mechanism in mammalian cells. Nature 2004;432:401-5.
40. Thorburn J, Moore F, Rao A et al. Selective inactivation of a Fas-associated death domain protein (FADD)-dependent apoptosis and autophagy pathway in immortal epithelial cells. Mol Biol Cell 2005;16:1189-99.
41. Bell BD, Leverrier S, Weist BM et al. FADD and caspase-8 control the outcome of autophagic signaling in proliferating T cells. Proc Natl Acad Sci USA 2008;105:16677-82.
42. Liu H, Pope RM. The role of apoptosis in rheumatoid arthritis. Curr Opin Pharmacol 2003;3:317-22.
43. Perlman H, Liu H, Georganas C et al. Differential expression pattern of the antiapoptotic proteins, Bcl-2 and FLIP, in experimental arthritis. Arthritis Rheum 2001;44: 2899-908.
44. Sugiyama M, Tsukazaki T, Yonekura A et al. Localisation of apoptosis and expression of apoptosis related proteins in the synovium of patients with rheumatoid arthritis. Ann Rheum Dis 1996;55:442-9.
45. Perlman H, Pagliari LJ, Liu H et al. Rheumatoid arthritis synovial macrophages express the Fas-associated death domain-like interleukin-1beta-converting enzymeinhibitory protein and are refractory to Fas-mediated apoptosis. Arthritis Rheum 2001;44:21-30.
46. Zhande R, Dauphinee SM, Thomas JA et al. FADD negatively regulates lipopolysaccharide signaling by impairing interleukin-1 receptor-associated kinase 1-MyD88 interaction. Mol Cell Biol 2007;27:7394-404.
47. Gomez-Angelats M, Cidlowski JA. Molecular evidence for the nuclear localization of FADD. Cell Death Differ 2003; 10:791-7.
48. Screaton RA, Kiessling S, Sansom OJ et al. Fas-associated death domain protein interacts with methyl-CpG binding domain protein 4: a potential link between genome surveillance and apoptosis. Proc Natl Acad Sci USA 2003;100:5211-6.
49. Scaffidi C, Volkland J, Blomberg I et al. Phosphorylation of FADD/MORT1 at serine 194 and association with a 70-kDa cell cycle-regulated protein kinase. J Immunol 2000;164:1236-42.
50. Alappat EC, Feig C, Boyerinas B et al. Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities. Mol Cell 2005;19:321-32.
51. Tourneur L, Mistou S, Schmitt A et al. Adenosine receptors control a new pathway of Fas-associated death domain protein expression regulation by secretion. J Biol Chem 2008;283:17929-38.
52. Kriebardis AG, Antonelou MH, Stamoulis KE et al. RBC-derived vesicles during storage: ultrastructure, protein composition, oxidation, and signaling components. Transfusion 2008;48:1943-53.
53. Berckmans RJ, Nieuwland R, Kraan MC et al. Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Res Ther 2005;7:R536-44.
54. Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol 185:1993-8.
55. Hasko G, Linden J, Cronstein B et al. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008;7:759-70.
56. He W, Cronstein B. The roles of adenosine and adenosine receptors in bone remodeling. Front Biosci 3: 888-95.
57. Bours MJ, Swennen EL, Di Virgilio F et al. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 2006;112:358-404.
58. Varani K, Padovan M, Govoni M et al. The role of adenosine receptors in rheumatoid arthritis. Autoimmun Rev 10: 61-4.
59. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-52.
60. Ramkumar V, Stiles GL, Beaven MA, Ali H. The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem 1993;268:16887-90.
61. Zarek PE, Huang CT, Lutz ER et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 2008;111:251-9.
62. Varani K, Massara A, Vincenzi F et al. Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. Arthritis Rheum 2009; 60:2880-91.
63. Kara FM, Doty SB, Boskey A et al. Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice. Arthritis Rheum 62:534-41.
64. Boyle DL, Sajjadi FG, Firestein GS. Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthritis Rheum 1996;39:923-30.
65. Erdmann AA, Gao ZG, Jung U et al. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 2005;105:4707-14.
66. Forrest CM, Harman G, McMillan RB et al. Modulation of cytokine release by purine receptors in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23: 89-92.
67. von Borstel RW, Wurtman RJ, Conlay LA. Chronic caffeine consumption potentiates the hypotensive action of circulating adenosine. Life Sci 1983;32:1151-8.
68. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-73.
69. Chan ES, Cronstein BN. Methotrexate-how does it really work? Nat Rev Rheumatol 6:175-8.
70. Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res 2005;54:273-80.
71. Rath-Wolfson L, Bar-Yehuda S, Madi L et al. IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis. Clin Exp Rheumatol 2006;24:400-6.
72. Ochaion A, Bar-Yehuda S, Cohn S et al. Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression. Arthritis Res Ther 2006;8:R169.
73. Silverman MH, Strand V, Markovits D et al. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol 2008;35:41-8.
74. Ochaion A, Bar-Yehuda S, Cohen S et al. The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvantinduced arthritis rats. Biochem Pharmacol 2008;76: 482-94.
75. Mazzon E, Esposito E, Impellizzeri D et al. CGS 21680, an agonist of the adenosine (A2A) receptor, reduces progression of murine type II collagen-induced arthritis. J Rheumatol 2011;38:2119-29.
76. Lalor PA, Mapp PI, Hall PA et al. Proliferative activity of cells in the synovium as demonstrated by a monoclonal antibody, Ki67. Rheumatol Int 1987;7: 183-6.
77. Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1995;96:1631-8.
78. Baier A, Meineckel I, Gay S et al. Apoptosis in rheumatoid arthritis. Curr Opin Rheumatol 2003;15:274-9.
79. Kobayashi T, Okamoto K, Kobata T et al. Novel gene therapy for rheumatoid arthritis by FADD gene transfer: induction of apoptosis of rheumatoid synoviocytes but not chondrocytes. Gene Ther 2000;7:527-33.
80. Okamoto K, Kobayashi T, Kobata T et al. Fas-associated death domain protein is a Fas-mediated apoptosis modulator in synoviocytes. Rheumatology 2000;39: 471-80.
81. Morel J, Audo R, Hahne M et al. Tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005;280:15709-18.
82. Tourneur L, Mistou S, Michiels FM et al. Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells. Oncogene 2003;22: 2795-804.